JAK2/STAT3 signaling pathway

The JAK2/STAT3 signaling pathway is an intracellular signal transduction cascade that relays cytokine and growth factor signals from the cell surface to the nucleus, coupling receptor engagement directly to changes in gene transcription. Janus kinase 2 (JAK2) is a non-receptor tyrosine kinase constitutively associated with the cytoplasmic tails of cytokine receptors; ligand binding — most prominently by Interleukin-6 (IL-6), but also by growth factors, leptin, and interferons — brings receptor-bound JAK2 molecules into proximity, where they activate one another by transphosphorylation and then phosphorylate Signal Transducer and Activator of Transcription 3 (STAT3) on its conserved tyrosine residue, Tyr705. Phosphorylated STAT3 (pSTAT3) dimerizes, translocates to the nucleus, and drives transcription of target genes governing proliferation, survival, angiogenesis, and inflammation, including antiapoptotic effectors such as B-cell lymphoma 2 (Bcl-2). Under normal physiology the cascade is transient and self-limiting, restrained by negative feedback from suppressor of cytokine signaling (SOCS) proteins; loss of that restraint yields the sustained, constitutive STAT3 activation characteristic of disease. Closely related receptor–kinase couplings, such as TYK2-JAK1, transduce overlapping cytokine inputs through the same STAT family.

The pathway's breadth of downstream output places it at the intersection of oncology, immunology, and metabolic disease. In tumors it integrates signals from the microenvironment — inflammatory cytokines including IL-6 and interleukin-1β, chemokines, and stromal mediators — and cooperates with Hypoxia-inducible factor 1-alpha (HIF-1α), Protein kinase B (PKB)/protein kinase B, mitogen-activated protein kinase 1 (MAPK1), and nuclear β-catenin to sustain glycolytic metabolic reprogramming, epithelial-mesenchymal transition, and immune evasion via checkpoint ligands of the PD-1/PD-L1 axis. Beyond cancer, JAK2/STAT3 activity contributes to renal tubulointerstitial fibrosis and ferroptosis in diabetic kidney disease, to microglia-driven neuroinflammation and pyroptosis after cerebral ischemia-reperfusion injury, and to inflammatory liver injury. Its therapeutic tractability is well established: ATP-competitive JAK inhibitors including ruxolitinib and momelotinib are used clinically in myelofibrosis, JAK2 serves as a benchmark target in structure-based drug design campaigns, and a large body of natural product pharmacology — spanning compounds such as bufalin, bruceine D, and rosmarinic acid — pursues STAT3 suppression as a mechanism of action.